What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025Blood

Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies

View Full Paper

Ask AI

Bookmark

Authors

Interim phase 1 study shows safety of CD7 CAR T-cell therapy in hematologic malignancies, indicating potential for disease remission.

Seventy-eight percent of patients achieved MRD-negative complete remission after CD7 CAR T-cell therapy, paving the way for haploidentical HSCT.
Overall survival and progression-free survival rates at 12 months post-CAR T-cell therapy were 54.8% and 48.7%, respectively.
Cytokine release syndrome was reported in 84.2% of patients, while 100% experienced grades 3-4 cytopenia.
Chronic graft-versus-host disease occurred in only one patient, supporting the safety of the approach.

Yu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Interim phase 1 study shows safety of CD7 CAR T-cell therapy in hematologic malignancies, indicating potential for disease remission.

Seventy-eight percent of patients achieved MRD-negative complete remission after CD7 CAR T-cell therapy, paving the way for haploidentical HSCT.
Overall survival and progression-free survival rates at 12 months post-CAR T-cell therapy were 54.8% and 48.7%, respectively.
Cytokine release syndrome was reported in 84.2% of patients, while 100% experienced grades 3-4 cytopenia.
Chronic graft-versus-host disease occurred in only one patient, supporting the safety of the approach.

Yu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark